Tag: Antibe Therapeutics Inc.
November 28, 2018
Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation,... January 21, 2016